Page last updated: 2024-09-05

enrasentan and 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide

enrasentan has been researched along with 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide in 1 studies

Compound Research Comparison

Studies
(enrasentan)
Trials
(enrasentan)
Recent Studies (post-2010)
(enrasentan)
Studies
(5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide)
Trials
(5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide)
Recent Studies (post-2010) (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide)
32207308

Protein Interaction Comparison

ProteinTaxonomyenrasentan (IC50)5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide (IC50)
Endothelin-1 receptorHomo sapiens (human)0.23
Endothelin-1 receptorRattus norvegicus (Norway rat)0.015

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boyd, SA; Chiou, WJ; Dixon, DB; Henry, KJ; Kozmina, NS; Liu, G; Marsh, KC; Nguyen, B; Opgenorth, TJ; Szczepankiewicz, BG; von Geldern, TW; Wasicak, J; Winn, M; Wu-Wong, JR1

Other Studies

1 other study(ies) available for enrasentan and 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide

ArticleYear
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
    Journal of medicinal chemistry, 1998, Aug-13, Volume: 41, Issue:17

    Topics: Administration, Oral; Animals; Atrasentan; Binding, Competitive; Biological Availability; CHO Cells; Cricetinae; Drug Design; Endothelin Receptor Antagonists; Humans; Kinetics; Male; Metabolic Clearance Rate; Molecular Conformation; Molecular Structure; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Transfection

1998